|
|
Clinical effect of Voriconazole+Itraconazole in the treatment of secondary fungal infections of hematological malignancies |
JIANG Peng-fei1 LIU Jia2▲ |
1.Department of Oncology and Hematology, Jingmen Traditional Chinese Medicine Hospital, Hubei Province, Jingmen 448000, China;
2.Department of Rehabilitation, Jingmen Traditional Chinese Medicine Hospital, Hubei Province, Jingmen 448000, China |
|
|
Abstract Objective To analyze the difference of efficacy of Voriconazole+Itraconazole and Voriconazole alone in the treatment of patients with secondary fungal infections of hematological malignancies.Methods A total of 120 patients with secondary fungal infections of hematological malignancies treated in our hospital from June 2017 to June 2018 were selected as the research objects.According to the sequence of admission, the patients were divided into observation group and reference group, with 60 cases in each group.Patients in the observation group were treated with Voriconazole+Itraconazole, and patients in the reference group were treated with Voriconazole alone.The therapeutic effect, the incidence of adverse reactions, the levels of inflammatory factors (tumor necrosis factor α [TNF-α], interleukin-4 [IL-4], interleukin-10 [IL-10], interleukin-12 [IL-12]) before and after treatment, improvement time of clinical symptoms (fever, cough, sputum, nausea, septic shock, and respiratory failure) were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05).Before treatment, there were no statistically significant differences in the contents of TNF-α, IL-12, IL-4 and IL-10 between the two groups (P<0.05).After treatment, the levels of TNF-α, IL-12 in both groups were lower than those before treatment, and the levels of IL-4 and IL-10 were higher than those before treatment, with statistical differences (P<0.05).After treatment, the levels of TNF-α and IL-12 in the observation group were lower than those in the control group, and the levels of IL-4 and IL-10 were higher than those in the control group, with statistical differences (P<0.05).The improvement time of fever, cough, sputum, nausea, septic shock, and respiratory failure in the observation group was shorter than that in the control group, and the difference was statistically significant (P<0.05).Conclusion The application of Voriconazole+Itraconazole in the treatment of patients with secondary fungal infections of hematological malignancies has definite clinical effects, and it can improve the clinical symptoms and inflammatory factor levels of patients as soon as possible, which is suitable for clinical application and promotion.
|
|
|
|
|
[1] |
刘杨,冯婉玉.北京大学人民医院血液科含伏立康唑的门诊处方分析[J].中国当代医药,2017,24(6):86-88.
|
[2] |
丰航,刘锦霞,李茁,等.恶性血液病抗真菌药物使用分析[J].中国药物与临床,2017,17(4):526-528.
|
[3] |
滕元姬,易雪丽,罗斌等.皮炎外瓶霉导致的真菌性腹膜炎1例[J].中国真菌学杂志,2017,12(6):368-370.
|
[4] |
毛盼盼,杜一民,张阳,等.伏立康唑预防HSCT 术后侵袭性真菌感染疗效及安全性的Meta分析[J].大理学院学报,2017,2(2):31-36.
|
[5] |
李德东,张浩榆,柴栋,等.卡泊芬净预防和治疗恶性血液病患者侵袭性真菌感染的Meta分析[J].中国临床药理学杂志,2017,33(5):452-455.
|
[6] |
陈凤华.伊曲康唑预防血液肿瘤患者化疗后真菌感染的临床分析[J].中国医药指南,2017,15(20):152-153.
|
[7] |
陆晖,李孟英,谭可平,等.不同真菌感染对肝衰竭患者病情及预后影响的研究[J].肝脏,2017,22(4):332-334.
|
[8] |
李云会,黎奇,白劲松,等.HIV/AIDS 患者深部真菌感染状况及药敏研究[J].皮肤病与性病,2018,40(2):18-21.
|
[9] |
范秋兰.卡泊芬净联合伏立康唑治疗恶性血液病继发侵袭性真菌感染的研究[J].首都食品与医药,2018,25(18):45.
|
[10] |
张新静,陆小威,苏佳,等.伏立康唑治疗慢性阻塞性肺疾病合并肺部真菌感染的临床效果及对炎性因子水平的影响分析[J].中国医学前沿杂志(电子版),2018,10(12):35-38.
|
[11] |
刘静,季海龙,赵芳,等.国产两性霉素B 单用或联合其他抗真菌药治疗恶性血液病并真菌感染54例临床分析[J].中国真菌学杂志,2018,13(2):83-86.
|
[12] |
梁玉丽,刘刚,温丽,等.长期化疗后相继出现肺、肝侵袭性真菌感染急性髓系白血病一例并文献复习[J].白血病·淋巴瘤,2018,27(9):548-550.
|
[13] |
张燕青,李小玲,林雪玉,等.肾移植患者伏立康唑与他克莫司药物相互作用的病例分析[J].海峡药学,2018,30(4):122-124.
|
[14] |
谢梅,骆艳妮,李娜,等.大蒜素注射液联合伏立康唑治疗肺部真菌感染的疗效观察[J].现代药物与临床,2019,34(1):112-116.
|
[15] |
张林,周舟,李爱国,等.血液系统恶性肿瘤感染患儿的病原菌分布及耐药性分析[J].儿科药学杂志,2019,25(2):44-47.
|
|
|
|